Liquid biopsy for the diagnosis of EBV-positive Burkitt's lymphoma in endemic areas - PubMed
5 hours ago
- #EBV-positive
- #Liquid biopsy
- #Burkitt's lymphoma
- Liquid biopsy evaluated for diagnosing EBV-positive Burkitt's lymphoma (BL) in endemic areas like sub-Saharan Africa.
- Study involved 377 children and young adults with suspected lymphoma in Tanzania and Uganda.
- Gold-standard diagnosis established via tissue morphology, immunohistochemistry, and dual histopathologist review.
- Six penalized logistic regression models trained using clinical features and circulating tumor DNA markers.
- Best-performing model achieved high diagnostic accuracy (AUC 0.95, sensitivity 0.86, specificity 0.95).
- External validation confirmed model performance (AUC 0.98).
- Liquid biopsy reduced median diagnostic turnaround time from 46.8 days to 6.5 days.
- Liquid biopsy provided the only diagnostic result in 42% of cases during multidisciplinary review.
- Findings suggest liquid biopsy can significantly reduce treatment delays in resource-limited settings.